OCSOculis Holding AG
$8.62-55% 1Y
$8.62
$8.5152 weeks$32.65
Is the business good?
How good a business is OCS?
Oculis Holding AG earns −79% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−79%
Return on invested capital · cost of capital 9.0% · 88 points below what the capital costs: growth destroys value
- Operating margin
- −7762%
Operating margin · Biotechnology median −77% · 12 months to Q2 2025
- Share count, year on year
- +56%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 5633%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −1242% |
| FY2021 | −1378% |
| FY2022 | −3550% |
| FY2023 | −9141% |
| FY2024 | −10671% |
| FY2025 | −6812% |
Details›
- Operating margin12 months to Q2 2025
- −7762%
- Net margin12 months to Q2 2025
- −9439%
- R&D as % of revenue
- 5633%
- Revenue, trailing twelve months
- $1.0M
- Net income, trailing twelve months
- −$96M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −79%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.